WhatsApp

New Combo Treatment May Delay Prostate Cancer Progression

You are here >> Home > Latest Updates > Prostate Cancer > New Combo…

Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR) An Open-Label, Randomized, Controlled, Phase II Study.DOI 10.1200JCO-25-01553

When prostate cancer returns in a few places after treatment, it’s called “oligorecurrent.” Doctors often use targeted radiation to these spots, called SBRT, to keep the cancer under control. But cancer often grows again.

A new study from UCLA tested whether adding a special radiation-based drug before SBRT could help. The drug is called 177Lu-PNT2002. It targets prostate cancer cells using a protein called PSMA.

The study included 92 men with up to five spots of returning cancer.

One group got only SBRT. The other group got two doses of the PSMA-targeting drug first, then SBRT.

The results showed the combo treatment worked better.

Cancer stayed away longer—almost 18 months versus about 7 months with SBRT alone.

Serious side effects were rare in both groups.

This means the new drug plus SBRT may help keep prostate cancer in check longer, without adding more side effects.

Men whose prostate cancer has come back in a few places may benefit from this kind of treatment.

Ask your doctor if this approach could be right for you.

Rate this post
dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.